Company intelligence / Profile preview

EryDel S.p.A.

Bresso (Milan), Italyorpha.net ↗

Ownership: Private
Employees: ~21
Development stage: Phase 3

Overview

EryDel's lead product EryDex is in Phase 3 development for Ataxia-Telangiectasia, a rare neurodegenerative disease with no approved treatments. The technology encapsulates dexamethasone sodium phosphate in the patient's own red blood cells for sustained therapeutic delivery over a monthly treatment period.

Therapeutic areas: Neurology
Modalities: Red blood cell-based drug delivery
Industry: Biotech

Drug pipeline

1 asset

dexamethasone 21-phosphate

Phase 3

Indications: Ataxia telangiectasia

Beyond the preview

Go deeper on EryDel S.p.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EryDel S.p.A..

Explore the full profile